Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia

Major options for second‐line therapy in adults with chronic immune thrombocytopenia (ITP) include splenectomy, rituximab, and thrombopoietin receptor agonists (TRAs). The American Society of Hematology guidelines recommend rituximab over splenectomy, TRAs over rituximab, and splenectomy or TRAs whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Goshua, George, Sinha, Pranay, Kunst, Natalia, Pischel, Lauren, Lee, Alfred Ian, Cuker, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365880/
https://www.ncbi.nlm.nih.gov/pubmed/35147241
http://dx.doi.org/10.1002/ajh.26497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365880/
https://www.ncbi.nlm.nih.gov/pubmed/35147241
http://dx.doi.org/10.1002/ajh.26497

Ejemplares similares